<DOC>
	<DOC>NCT01778023</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.</brief_summary>
	<brief_title>Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Informed consent obtained from subject's parents or legally acceptable representative before any trialrelated activities. (Trialrelated activities are any procedure that would not have been performed during normal management of the subject.) Prepubertal status (males aged from 4 to 11 [both inclusive], females aged from 4 to 9 [both inclusive]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used) Height below 3 percentile Bone age below or equal to 12 year Epiphyses confirmed as open in patients at least 10 years or more of age Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (folliclestimulating hormone), LH (luteinising hormone), TSH (thyroidstimulating hormone)) Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated) Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone Bone age is advanced over chronological age more than 3 years Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia Prior history of intracranial hypertension Hypertrophic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>